Greenwich LifeSciences Receives Second Nasdaq Notice for Late SEC Filing
Greenwich LifeSciences received a second Nasdaq notice for late filing of its Form 10-Q, following a prior notice for a late Form 10-K. The company's stock continues trading on the Nasdaq Capital Market while it works to file the overdue reports.
Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, has received a second Nasdaq notice for noncompliance with listing rules due to a late SEC filing. The company received a notice on May 20, 2026, for failing to file its Form 10-Q for the quarter ended March 31, 2026, following an earlier notice on April 16, 2026, for not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
Both notices cite noncompliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. Neither notice has an immediate effect on the listing or trading of GLSI's common stock, which continues to trade on the Nasdaq Capital Market under the symbol "GLSI."
The company plans to file the Form 10-K as soon as possible, working with two auditors where each auditor is responsible for their own periods ending in 2024 and 2025.
Greenwich LifeSciences is focused on the development of GP2 (also referred to as GLSI-100), a peptide-based immunotherapy designed to prevent breast cancer recurrences in patients who have previously undergone surgery. The company is currently running the Phase III FLAMINGO-01 trial evaluating Fast Track-designated GLSI-100.
As of the latest available data, the company reported research and development expenses of $17.5 million for the year ended December 31, 2025, compared to $12.9 million for the year ended December 31, 2024. The unaudited cash balance was approximately $10.5 million as of March 31, 2026.